Generic Name
Dichlorphenamide
Brand Names
Keveyis, Ormalvi
FDA approval date: December 13, 2021
Classification: Carbonic Anhydrase Inhibitor
Form: Tablet
What is Keveyis (Dichlorphenamide)?
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment